New Advances in Dual Therapy for HER2+ Breast Cancer Improve Treatment Choices and Reduce Resistance

Compilation
Dual HER2 inhibition has emerged as one of the most promising treatment strategies for HER2+ breast cancer. Hospital Clinic of Barcelona through the Institute of Biomedical Research Augusta Pi and Sunier (Idibaps) and in collaboration with the Dana Farber Cancer Institute in Boston presented the latest advances in this therapy. So they indicated it’s a double action increases the effectiveness of therapy and helps reduce manifestations of resistance.

HER2 dual therapy consists of a combination of monoclonal antibodies and tyrosine kinase inhibitor drugs. They act synergistically reduce the progression of the disease. This combination allows it to attack the HER2 receptor on the cell surface and interfere with the signaling pathways that cancer cells activate to divide and multiply.

Thus, the advances reported in the study show a possible solution to the common problem of long-term treatment for patients with advanced cancer.

Improving the accuracy of patient selection is one of the main goals

One of the main tasks of the research group is improve the accuracy of patient selection who may benefit most from this treatment. Identification of specific biomarkers is a key tool for predicting each patient’s response to HER2 dual therapy. According to experts, the use of biomarkers allows you to adjust treatment on an individual basis. This avoids unnecessary side effects in those who would not benefit from a dual approach. They also focus on patients most likely to respond.

This advance is particularly important in the treatment of advanced HER2+ breast cancer. For this type of cancer, dual inhibition is an alternative. less aggressive compared to other treatments such as chemotherapy. Preliminary data from the study suggest that dual therapy may prolong disease control. At the same time, they note that this reduces the impact of accumulated toxicity, which is a decisive advantage for improving the quality of life of patients. Moreover, the emphasis on dual inhibition opens the door to new research and possible therapeutic combinations.

The study also highlights the importance of collaborative research between prestigious institutions such as Clinic-Idibaps and the Dana Farber Cancer Institute. This allows integrate both a clinical perspective and the latest advances in biomedical research. This collaboration has been fundamental to advancing knowledge of the molecular pathways of HER2+ breast cancer, allowing the development of more specific and personalized approaches that maximize the benefits of dual inhibition.

Oncology continues to move towards increasingly targeted and specific treatments, and HER2+ breast cancer is a clear example of how ongoing research allows us to offer innovative and less invasive treatment methods.